Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR - PubMed (original) (raw)

. 2005 Dec;37(12):1315-6.

doi: 10.1038/ng1671. Epub 2005 Oct 30.

Affiliations

• PMID: 16258541
• DOI: 10.1038/ng1671

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR

Daphne W Bell et al. Nat Genet. 2005 Dec.

Abstract

Somatic activating mutations in EGFR identify a subset of non-small cell lung cancer that respond to tyrosine kinase inhibitors. Acquisition of drug resistance is linked to a specific secondary somatic mutation, EGFR T790M. Here we describe a family with multiple cases of non-small cell lung cancer associated with germline transmission of this mutation. Four of six tumors analyzed showed a secondary somatic activating EGFR mutation, arising in cis with the germline EGFR mutation T790M. These observations implicate altered EGFR signaling in genetic susceptibility to lung cancer.

PubMed Disclaimer

Similar articles

• Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
  Wong KK. Wong KK. Lung Cancer. 2008 Jun;60 Suppl 2:S10-8. doi: 10.1016/S0169-5002(08)70100-4. Lung Cancer. 2008. PMID: 18513579 Review.
• Detection of low-level EGFR T790M mutation in lung cancer tissues.
  Oh JE, An CH, Yoo NJ, Lee SH. Oh JE, et al. APMIS. 2011 Jul;119(7):403-11. doi: 10.1111/j.1600-0463.2011.02738.x. Epub 2011 May 14. APMIS. 2011. PMID: 21635547
• Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
  Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T. Kosaka T, et al. Clin Cancer Res. 2006 Oct 1;12(19):5764-9. doi: 10.1158/1078-0432.CCR-06-0714. Clin Cancer Res. 2006. PMID: 17020982
• Epidermal growth factor receptor mutations in lung cancer.
  Sharma SV, Bell DW, Settleman J, Haber DA. Sharma SV, et al. Nat Rev Cancer. 2007 Mar;7(3):169-81. doi: 10.1038/nrc2088. Nat Rev Cancer. 2007. PMID: 17318210 Review.

Cited by

• Detection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction.
  Xu Q, Zhu Y, Bai Y, Wei X, Zheng X, Mao M, Zheng G. Xu Q, et al. Onco Targets Ther. 2015 Jun 22;8:1533-41. doi: 10.2147/OTT.S84938. eCollection 2015. Onco Targets Ther. 2015. PMID: 26124670 Free PMC article.
• Targeting the dimerization of epidermal growth factor receptors with small-molecule inhibitors.
  Yang RY, Yang KS, Pike LJ, Marshall GR. Yang RY, et al. Chem Biol Drug Des. 2010 Jul;76(1):1-9. doi: 10.1111/j.1747-0285.2010.00986.x. Epub 2010 May 4. Chem Biol Drug Des. 2010. PMID: 20456371 Free PMC article.
• Cancer genomics and inherited risk.
  Stadler ZK, Schrader KA, Vijai J, Robson ME, Offit K. Stadler ZK, et al. J Clin Oncol. 2014 Mar 1;32(7):687-98. doi: 10.1200/JCO.2013.49.7271. Epub 2014 Jan 21. J Clin Oncol. 2014. PMID: 24449244 Free PMC article.
• Cancer drug resistance: an evolving paradigm.
  Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Holohan C, et al. Nat Rev Cancer. 2013 Oct;13(10):714-26. doi: 10.1038/nrc3599. Nat Rev Cancer. 2013. PMID: 24060863 Review.
• Targeted inhibition of kinases in cancer therapy.
  Baker SJ, Reddy EP. Baker SJ, et al. Mt Sinai J Med. 2010 Nov-Dec;77(6):573-86. doi: 10.1002/msj.20220. Mt Sinai J Med. 2010. PMID: 21105121 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • GlyGen glycoinformatics resource
  • Pharmacogenomics Knowledge Base

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal